Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent

a crosslinking agent and immune response technology, applied in the field of enhancing immune responses, can solve the problems that the immune response to certain viruses and tumor cells has been difficult to augment using art recognized methods, and achieve the effects of enhancing the immune response of the subject to the antigen, and enhancing the immune respons

Inactive Publication Date: 2006-03-14
GENETICS INST INC
View PDF12 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to methods for improving the body's ability to fight off invading germs or other harmful microorganisms. This can be achieved through giving certain substances called "costimulator molecules," which are small proteins found within cells that stimulate the immune system when exposed to specific types of bacteria or viruses. These agents help protect against these harmful organisms from being spread throughout their environment.

Problems solved by technology

This patent describes various technical problem addressed in this patent text relating to improving the effectiveness of immunotherapy against cancer. Current methods have limitations such as lack of targeting ability, difficulty in controlling the immunosuppressive effects of other molecular targets, and potential side effects like inflammatory responses caused by cytokines released from activated helper T cells. Therefore, there is a need for new ways to improve these immunocompounds' properties and functions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
  • Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
  • Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent

Examples

Experimental program
Comparison scheme
Effect test

example 1

Soluble Costimulatory Molecules Enhance CTL Responses

[0116]Optimal T cell activation requires both signaling through the T cell receptor and co-stimulation. B7-1 and B7-2 are two potent co-stimulatory molecules on the surface of APCs. The effects of a soluble form of B7-2 on in vivo T cell responses have been examined. The soluble molecule is a chimeric protein containing the extra-cellular domain of B7-2 fused to the Fc region of mouse IgG2a. Administration of B7-2Ig fusion protein at the time of immunization with class II restricted peptides significantly enhanced antigen-specific T cell proliferation and cytokine responses. B7-2Ig administration also enhanced the CTL response to immunization with a class I-restricted peptide. Enhancement of the CTL response by B7-2Ig was significantly increased in the presence of a T helper cell response to class II-restricted peptides. These findings demonstrate the immune stimulatory activity of a soluble protein form of costimulatory molecules, e

example 2

Materials and Methods Used in Example 2

[0150]The expression plasmids for the murine B7-1-IgGIgG and B7-2-IgG2a fusion proteins were constructed by joining the DNA encoding the signal and extracellular domains of murine B7-1 or B7-2 to the DNA encoding the hinge-CH2—CH3 domains derived from a murine IgG2a antibody. The cysteine residues within the antibody hinge region remained conserved such that the mB7-1-IgGIgG2a or mB7-2-IgG2a produced is dimeric and bivalent. Fusion proteins were generated in which the IgG2a region is mutated in order to prevent binding by high affinity Fc receptors and complement activation (designated B7-IgG2mut). The following amino acid residues in the CH2 domain were replaced by alanine: leucine at position #235, glutamic acid at #318, lysine at #320, and lysine at #322. For production of B7-IgG protein, the plasmids were expressed in CHO cell lines and the proteins were isolated.

[0151]P815 is a mastocytoma derived tumor cell line that grows as a solid tumor a

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Immunogenicityaaaaaaaaaa
Login to view more

Abstract

Methods of enhancing immune responses in which soluble forms of costimulatory molecules, e.g., B7 molecules, are administered to augment immune responses to antigens, e.g., to tumor cells and infectious agents are provided. The subject methods are useful for both prophylactic and therapeutic immunization of subjects.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner GENETICS INST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products